Abstract: The present invention relates to embodiments of: (1) a unitary holographic drive head assembly mounting structure; (2) an assembly comprising a unitary holographic drive head assembly mounting structure and a plurality of holographic drive head components and/or subassemblies; (3) a subassembly comprising a spatial light modulator, detector array, and a beam splitter; (4) a device comprising a spatial light modulator and a physical aperture positioned over or an imaged aperture projected onto the photoactive area of the spatial light modulator; (5) a system for optically aligning or pointing a laser in a holographic drive head assembly; (6) a light source subassembly comprising a laser, a fiber coupling lens; and an optical fiber having a fiber connector ready output end; and (7) a light source subsystem comprising a laser source, beam conditioning optics, fiber coupling optics for receiving the conditioned light beam, and a fiber optic connector for receiving the conditioned light beam from the fiber couplin

Abstract: Substituted 1,2,4-triazolo[1,5-c]pyrimido[1,4]azines have been found to have potent bronchodilator activity. Pharmacological methods for inducing bronchodilation using such compounds, pharmaceutical compositions containing such compounds, and synthetic intermediates for preparing such compounds are also described.

Abstract: Substituted 1,2,4-triazolo[1,5-c]pyrimido[1,4]-azines have been found to have potent bronchodilator activity. Pharmacological methods for inducing bronchodilation using such compounds, pharmaceutical compositions containing such compounds, and synthetic intermediates for preparing such compounds are also described.

Abstract: Substituted 1,2,4-triazolo[1,5-c]pyrimido[1,4]-azines have been found to have potent bronchodilator activity. Also, pharmacological methods for inducing bronchodilation using such compounds, pharmaceutical compositions containing such compounds, and synthetic intermediates, including 1,2,4-triazolo[4,3-c]-pyrimido[1,4]azines, for preparing such compounds.

Abstract: Substituted 1,2,4-triazolo[1,5-a]triazines as bronchodilators are disclosed. Pharmaceutical formulations comprising such compounds and pharmacological methods of using such compounds are also described.

Abstract: The present invention relates to metabolites of 2,5-diethyl-7-(4-thiomorpholino)-1,2,4-triazolo[1,5-c]-pyrimidine which are active as bronchodilators.

Abstract: Substituted triazolo[4,3-c]pyrimidines which are bronchodilators. The pharmacological use of these compounds, pharmaceutical compositions containing these compounds, and synthetic intermediates for the preparation of these compounds are also described.

Abstract: Piperidino-substituted pyrimidines which are intermediates for preparing piperidino-substituted imidazo-[1,5-c]pyrimidines which are bronchodilators.

Abstract: 1,2,4-Triazolo[1,5-c]pyrimidines substituted at the 7 position through a nitrogen atom which is part of a 1-oxo- or 1,1-dioxothiomorpholine ring have been found to have potent bronchodilator activity. Pharmacological methods of using these compounds and pharmaceutical compositions containing these compounds are also disclosed.

Abstract: 1,2,4-Triazolo[1,5-c]pyrimidines substituted at the 5 or 7 positions through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity. Methods for inducing bronchodilation, pharmaceutical compositions and synthetic processes are also disclosed.

Abstract: Imidazo[1,2,-c]pyrimidines which are bronchodilators. Pharmacological methods of using these compounds, pharmaceutical compositions containing these compounds, and synthetic intermediates for preparing these compounds are also described.

Abstract: 1,2,4-Triazolo[4,3-c]pyrimidines substituted at the 5 or 7 position through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity and to be useful synthetic intermediates in the preparation of 1,2,4-triazolo[1,5-c]pyrimidines. Methods for inducing bronchodilation, pharmaceutical compositions, and synthetic processes and intermediates are also described.

Abstract: Substituted triazolo[4,3-c]pyrimidines which are bronchodilators. The pharmacological use of these compounds, and synthetic intermediates for the preparation of these compounds are also described.

Abstract: Substituted triazolo[1,5-c]pyrimidines which are bronchodilators. The pharmacological use of these compounds and pharmaceutical compositions containing these compounds are also described.

Abstract: A process for preparing compounds of the formula ##STR1## wherein X is sulfur or oxygen; and R.sup.1 and R.sup.2 are independently selected from the group consisting of H and an alkyl group containing 1 to about 4 carbon atoms, or R.sup.1 and R.sup.2 are fused to form a benzene ring which is optionally substituted by one or more substituents independently selected from the group consisting of an alkyl group containing 1 to about 4 carbon atoms, an alkoxy group containing 1 to about 4 carbon atoms, and halogen. The process involves reacting together a 2-aminooxazole, 2-aminobenzoxazole, 2-aminothiazole or 2-aminobenzothiazole, an alkyl tetrazol-5-ylacetate, and a trialkyl orthoformate and cyclizing the resulting intermediate.

Abstract: Imidazo[1,2-c]pyrimidines which are bronchodilators. Pharmacological methods of using these compounds, pharmaceutical compositions containing these compounds, and synthetic intermediates for preparing these compounds are also described.

Abstract: Substituted imidazo[1,5-c]pyrimidines have been found to have potent bronchodilator activity. Pharmacological methods, pharmaceutical compositions and synthetic intermediates are also disclosed.

Abstract: 1,2,4-Triazolo[4,3-c]pyrimidines substituted at the 5 or 7 position through a nitrogen atom which is part of a heterocyclic ring have been found to have potent bronchodilator activity and to be useful synthetic intermediates in the preparation of 1,2,4-triazolo[1,5-c]-pyrimidines. Methods for inducing bronchodilation, pharmaceutical compositions, and synthetic processes and intermediates are also described.

Abstract: 3-(1H-tetrazole-5-yl)-4H-pyrimido[2,1-b]-benzoxazol-4-ones are disclosed as anti-allergic compounds. Pharmaceutically acceptable salts, pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

Abstract: A process for preparing compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from the group consisting of H, an alkyl group containing 1 to about 4 carbon atoms, an alkoxy group containing 1 to about 4 carbon atoms and halogen. The process involves reacting together a 2-aminopyridine, an alkyl tetrazol-5-ylacetate, and a trialkyl orthoformate and cyclizing the resulting intermediate.